Jefferies cuts Boston Scientific stock price target on growth outlook

The key issue is not the quarter itself but the reset in the company’s medium-term compounding rate. A downgrade from “double-digit growth” to high-single-digit growth compresses the stock’s quality multiple more than the modest EPS revision suggests, because healthcare equipment names are typically priced on durable runway rather than near-term beats. That makes the market’s reaction rational if investors had been anchoring on 10%+ organic growth as a structural floor.

Second-order, the pressure likely broadens beyond BSX. Slower Watchman and rhythm momentum imply fewer share gains in adjacent high-margin franchises, which can force heavier promo intensity or rep activity across competing structural heart and EP players. The bigger risk is that this is not a one-off product hiccup but an indication that the post-pandemic elective/procedural recovery is normalizing faster than consensus, which would also temper expectations for supplier order growth and implant mix.

The buyback announcement is supportive but mostly defensive unless the operating trend stabilizes. A $2B repurchase can cushion downside over the next 1-2 quarters, but it does not change the market’s focus on whether 2026 guidance was cut once or is the first step in a series of resets. If management can re-accelerate urology and show stabilization in rhythm/Watchman over the next two reporting cycles, the name can re-rate; if not, the stock can remain cheap for a reason.

Contrarian view: the selloff may be overdone if investors are extrapolating the guidance cut into a long-lived erosion story. At roughly this valuation, the stock is pricing in a much deeper structural problem than a sub-10% growth profile, and medtech franchises with strong cash flow often bottom before guidance does. The best asymmetry is not chasing the dip outright, but waiting for evidence that the revised base is real and then buying the first quarter where guide-down risk disappears.